News

Almirall secures 5th partnership
Enlarge image

BusinessSpainItaly

Almirall secures 5th partnership

15.10.2012 - Patients in Australia and New Zealand will also receive Almirall's Aclidinium against the lung disease COPD. Invida is the licensing partner.

After the approval of Aclidinium by the European Commission in July and the following deal with Italian Menarini Group to commercialise the drug in most of Europe in July, Barcelona-based Almirall S.A. has inked a marketing partnership with Invida Holdings Private Limited, a member of the Menarini Group, to sell the drug on the fifth continent . Invida gains the commercial rights for Aclidinium in Australia and New Zealand, with the deal including both monotherapy and combination therapy (with Formoterol). Both treatments work against Chronic Obstructive Pulmonary Disease (COPD), where the drug relieves the tension in the muscles around the lungs to improve airflow.

COPD makes breathing difficult and is often caused by cigarette smoking. It is estimated that around 2 million people in Australia suffer from the disease, where it is the sixth most common cause of death among men and seventh among women, Almirall said. Financial details of the agreement have not been disclosed.  Eduardo Sanchiz, Chief Executive Officer of Almirall, states: "Together with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD. With this new agreement Aclidinium, via partners or Almirall's own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe, where we already have secured four license agreements in total." In Germany and Denmark, Aclidinium bromide is already on the market. It works as a long-acting inhaled muscarinic antagonist - sometimes referred to as an anticholinergic -, which has a long residence time at M3 receptors and a shorter residence time at M2 receptors. It is designed to be rapidly broken down in plasma into two major inactive metabolites, explaining its high topical efficacy but low propensity for systemic anticholinergic effects. When taken by inhalation, Aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction.   

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/almirall-secures-5th-partnership.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)2.30 EUR27.78%
  • SAREUM HOLDINGS (UK)0.76 GBP26.67%
  • PROTHENA PLC (IE)55.46 USD7.46%

FLOP

  • RENEURON (UK)3.00 GBP-4.46%
  • PHARMING (NL)0.24 EUR-4.00%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.46 USD50.9%
  • VERNALIS (UK)44.00 GBP34.4%

FLOP

  • SANTHERA (CH)55.30 CHF-26.4%
  • MOLOGEN (D)2.30 EUR-22.0%
  • NICOX (F)10.85 EUR-11.4%

TOP

  • KARO BIO (S)30.80 SEK1849.4%
  • NICOX (F)10.85 EUR474.1%
  • SAREUM HOLDINGS (UK)0.76 GBP230.4%

FLOP

  • BB BIOTECH (D)45.30 EUR-84.6%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016